Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.

KURA

Kura Oncology (KURA)

Kura Oncology Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:KURA
일자시간출처헤드라인심볼기업
2024/05/2107:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
2024/05/2105:19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KURAKura Oncology Inc
2024/05/1420:30GlobeNewswire Inc.Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AMLNASDAQ:KURAKura Oncology Inc
2024/05/0820:30GlobeNewswire Inc.Kura Oncology to Participate in Bank of America Securities Healthcare ConferenceNASDAQ:KURAKura Oncology Inc
2024/05/0320:30GlobeNewswire Inc.Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KURAKura Oncology Inc
2024/05/0305:05GlobeNewswire Inc.Kura Oncology Reports First Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
2024/04/2520:30GlobeNewswire Inc.Kura Oncology to Report First Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
2024/04/2220:30GlobeNewswire Inc.Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AMLNASDAQ:KURAKura Oncology Inc
2024/04/1020:30GlobeNewswire Inc.Kura Oncology to Participate in Stifel Targeted Oncology ForumNASDAQ:KURAKura Oncology Inc
2024/04/0520:30GlobeNewswire Inc.Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KURAKura Oncology Inc
2024/03/0621:30GlobeNewswire Inc.Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell CarcinomaNASDAQ:KURAKura Oncology Inc
2024/03/0207:00GlobeNewswire Inc.Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KURAKura Oncology Inc
2024/02/2806:52Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KURAKura Oncology Inc
2024/02/2806:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KURAKura Oncology Inc
2024/02/2806:01GlobeNewswire Inc.Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KURAKura Oncology Inc
2024/02/2621:30GlobeNewswire Inc.Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid LeukemiaNASDAQ:KURAKura Oncology Inc
2024/02/2221:30GlobeNewswire Inc.Kura Oncology to Participate in Three Upcoming Investor ConferencesNASDAQ:KURAKura Oncology Inc
2024/02/2021:30GlobeNewswire Inc.Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:KURAKura Oncology Inc
2024/02/1606:01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:KURAKura Oncology Inc
2024/02/1514:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KURAKura Oncology Inc
2024/02/1507:58Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KURAKura Oncology Inc
2024/02/1407:23Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KURAKura Oncology Inc
2024/02/1007:21Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:KURAKura Oncology Inc
2024/02/0221:30GlobeNewswire Inc.Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KURAKura Oncology Inc
2024/02/0107:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
2024/02/0107:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
2024/02/0107:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
2024/02/0107:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
2024/01/3106:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KURAKura Oncology Inc
2024/01/3021:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KURAKura Oncology Inc
 검색 관련기사 보기:NASDAQ:KURA

최근 히스토리

Delayed Upgrade Clock